Regeneron Pharmaceuticals Inc. has emerged victorious in an antitrust lawsuit against Amgen Inc., with a federal court jury in Delaware finding that Amgen violated antitrust and tort laws. The jury concluded that Amgen engaged in a bundling scheme that unlawfully leveraged its anti-inflammatory drugs, Enbrel and Otezla, to persuade pharmacy benefit managers to exclusively select Repatha over Regeneron's Praluent in the PCSK9 category. This decision resulted in Amgen being found in violation of the Clayton Act, the Sherman Act, and several state laws. Consequently, Regeneron was awarded $135.6 million in compensatory damages and $271.2 million in punitive damages. Regeneron has expressed satisfaction with the verdict, emphasizing the importance of fair competition in ensuring patient access to innovative treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.